Q-omics provides the consensus-scored MXRA5 profile across patient tissues and cancer cell-line models. MXRA5 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, MXRA5 is differentially expressed in 15, with the highest sampling consensus in KICH. Additionally, MXRA5 protein abundance shows 21,007 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight UVM, KICH, and PDAC as cancer lineages where MXRA5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MXRA5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MXRA5 survival associations across molecular data types. MXRA5 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (15) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MXRA5 RNA expression–survival associations across cancer types. High MXRA5 expression shows unfavorable associations in UVM, LGG, ACC and CESC, but favorable associations in LAML and UCS. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .003). Together, the overview and detailed table identify UVM as the clearest survival context for MXRA5 RNA expression.
This table summarizes MXRA5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 7. The strongest signals are observed in HNSC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for MXRA5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MXRA5 shows lower tumor expression in KICH and KIRC and higher tumor expression in HNSC, LUAD, STAD and BRCA. The KICH box plot shows higher MXRA5 RNA expression in normal versus tumor tissue (log2 FC = −3.098, t-test p < 0.001).
This table shows molecular features associated with MXRA5 in patient tissues and cancer cell lines. In patient samples, MXRA5 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, MXRA5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and LARGE_INTESTINE.
